AAAAAA

   
Results: 1-7 |
Results: 7
IMMUNOBIOLOGICAL EFFECTS OF INTERLEUKIN-2, INTERLEUKIN-12 OR INTERLEUKIN-2 PLUS INTERLEUKIN-12 IN METASTATIC CANCER-PATIENTS
Authors: LISSONI P BARNI S MANDALA M ROVELLI F CANGEMI G FUMAGALLI L PIRATO D VIGORE L ROSELLI MG TANCINI G VIGANO MG GIANI L
Citation: P. Lissoni et al., IMMUNOBIOLOGICAL EFFECTS OF INTERLEUKIN-2, INTERLEUKIN-12 OR INTERLEUKIN-2 PLUS INTERLEUKIN-12 IN METASTATIC CANCER-PATIENTS, International journal of immunotherapy, 14(1), 1998, pp. 41-44
NEUROIMMUNOTHERAPY WITH LOW-DOSE SUBCUTANEOUS INTERLEUKIN-2 PLUS MELATONIN IN AIDS PATIENTS WITH CD4 CELL NUMBER BELOW 200 MM(3) - A BIOLOGICAL PHASE-II STUDY/
Authors: LISSONI P VIGORE L RESCALDANI R ROVELLI F BRIVIO F GIANI L BARNI S TANCINI G ARDIZZOIA A VIGANO MG
Citation: P. Lissoni et al., NEUROIMMUNOTHERAPY WITH LOW-DOSE SUBCUTANEOUS INTERLEUKIN-2 PLUS MELATONIN IN AIDS PATIENTS WITH CD4 CELL NUMBER BELOW 200 MM(3) - A BIOLOGICAL PHASE-II STUDY/, Journal of biological regulators and homeostatic agents, 9(4), 1995, pp. 155-158
INTERLEUKIN-2, MELATONIN AND INTERLEUKIN-12 AS A POSSIBLE NEUROIMMUNECOMBINATION IN THE BIOTHERAPY OF CANCER
Authors: LISSONI P PITTALIS S ROVELLI F VIGORE L ROSELLI MG BRIVIO F
Citation: P. Lissoni et al., INTERLEUKIN-2, MELATONIN AND INTERLEUKIN-12 AS A POSSIBLE NEUROIMMUNECOMBINATION IN THE BIOTHERAPY OF CANCER, Journal of biological regulators and homeostatic agents, 9(2), 1995, pp. 63-66
LYMPHOCYTOSIS DECLINE IS NOT RESPONSIBLE FOR TUMOR PROGRESSION IN CANCER-PATIENTS CHRONICALLY TREATED WITH INTERLEUKIN-2
Authors: LISSONI P BARNI S ANDRES M SCARDINO E VIGORE L VEZZO R RESCALDANI R TANCINI G
Citation: P. Lissoni et al., LYMPHOCYTOSIS DECLINE IS NOT RESPONSIBLE FOR TUMOR PROGRESSION IN CANCER-PATIENTS CHRONICALLY TREATED WITH INTERLEUKIN-2, Tumori, 80(4), 1994, pp. 283-285
LYMPHOCYTOSIS DECLINE IS NOT RESPONSIBLE FOR TUMOR PROGRESSION IN CANCER-PATIENTS CHRONICALLY TREATED WITH INTERLEUKIN-2
Authors: LISSONI P BARNI S ANDRES M SCARDINO E VIGORE L VEZZO R RESCALDANI R TANCINI G
Citation: P. Lissoni et al., LYMPHOCYTOSIS DECLINE IS NOT RESPONSIBLE FOR TUMOR PROGRESSION IN CANCER-PATIENTS CHRONICALLY TREATED WITH INTERLEUKIN-2, Tumori, 80(4), 1994, pp. 283-285
INVIVO BIOLOGICAL RESULTS OF THE ASSOCIATION BETWEEN INTERLEUKIN-2 AND INTERLEUKIN-3 IN THE IMMUNOTHERAPY OF CANCER
Authors: LISSONI P BARNI S TISI E ROVELLI F PITTALIS S RESCALDANI R VIGORE L BIONDI A ARDIZZOIA A TANCINI G
Citation: P. Lissoni et al., INVIVO BIOLOGICAL RESULTS OF THE ASSOCIATION BETWEEN INTERLEUKIN-2 AND INTERLEUKIN-3 IN THE IMMUNOTHERAPY OF CANCER, European journal of cancer, 29A(8), 1993, pp. 1127-1132
IMMUNOTHERAPY WITH LOW-DOSE SUBCUTANEOUS INTERLEUKIN-2 PLUS INTERFERON-BETA AS A 2ND-LINE THERAPY FOR METASTATIC COLORECTAL-CARCINOMA
Authors: BARNI S LISSONI P ARDIZZOLA A VIGORE L VEZZO R RESCALDANI R TANCINI G
Citation: S. Barni et al., IMMUNOTHERAPY WITH LOW-DOSE SUBCUTANEOUS INTERLEUKIN-2 PLUS INTERFERON-BETA AS A 2ND-LINE THERAPY FOR METASTATIC COLORECTAL-CARCINOMA, Tumori, 79(5), 1993, pp. 343-346
Risultati: 1-7 |